US Patent

US10993952 — Stable ready to use cyclophosphamide liquid formulations

Formulation · Assigned to Leiutis Pharmaceutials LLP · Expires 2036-02-15 · 10y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects stable, ready-to-use liquid formulations of Cyclophosphamide for parenteral use.

USPTO Abstract

The present invention relates to stable ready to use liquid formulations of Cyclophosphamide for parenteral use. The ready to use composition comprises Cyclophosphamide dissolved in a solvent system comprising a solvent, cosolvent(s) and antioxidant(s).

Drugs covered by this patent

Cytoxan (Lyophilized) (cyclophosphamide) · Baxter

Patent Metadata

Patent number: US10993952
Jurisdiction: US
Classification: Formulation
Expires: 2036-02-15
Drug substance claim: No
Drug product claim: Yes
Assignee: Leiutis Pharmaceutials LLP
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.